<DOC>
	<DOCNO>NCT00038519</DOCNO>
	<brief_summary>The purpose study study safety efficacy Amprenavir/ritonavir saquinavir/ritonavir HIV infect patient fail Kaletra second protease inhibitor base HAART .</brief_summary>
	<brief_title>Amprenavir/Ritonavir Saquinavir/Ritonavir HIV-Infected Subjects Following Failure With Kaletra Their Second Protease Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion : Subject must remain current antiretroviral therapy screen new regimen initiate . Subject demonstrate reduced susceptibility lopinavir . Subject 's two recent viral load obtain least 16 week lopinavir/ritonavir therapy , still Kaletra therapy must least 1,000 copies/mL . The Kaletra regimen must subject 's second PI contain regimen must contain PIs . Subject least 18 year age . Subject treat active opportunistic infection within 30 day screen . Exclusion : Subject history active substance abuse psychiatric illness could preclude compliance protocol . Female subject pregnant lactating . Use Investigational drug within 30 day prior initiation drug dosing . Subject receive systemic chemotherapy . Subject history acute chronic pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>treatment experience</keyword>
	<keyword>HIV</keyword>
</DOC>